Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Links:
Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomi…
https://acrabstracts.org/abstract/vunakizumab-in-patients-with-active-psoriatic…
18-11-2024